The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839

Material

Thursday 5 Nov268 filings read · 268 material

  • 8-KFiled 5 Nov 2026Biotech

    Protagonist Therapeutics, IncPTGX

    8-K · Item 2.02 — Results of operations

    FDA approved MIMRYLO (rusfertide) for polycythemia vera, triggering $275M in payments to Protagonist. Q3 2026 net income $220M vs. prior-year loss of $39M. Strong cash position of $835M supports pipeline advancement and $300M share repurchase program.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Cryoport, Inc.CYRX

    8-K · Item 2.02 — Results of operations

    Cryoport reported Q3 2026 revenue of $50.2M (+14% YoY), with commercial CGT revenue up 20%. Company raised full-year 2026 guidance to $197–199M. Achieved positive adjusted EBITDA of $1.1M and supports record 788 clinical trials and 23 approved therapies.

    Recognition: Balanced 60 → Strong 66

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Corvus Pharmaceuticals, Inc.CRVS

    8-K · Item 2.02 — Results of operations

    Corvus reports Q3 2026 results with $202.9M cash (runway to Q2 2028), multiple soquelitinib trials on track including Phase 3 PTCL, Phase 2 atopic dermatitis, and new Phase 1b hidradenitis suppurativa. Angel Pharma completed first cohort enrollment with data expected March 2027.

    Gap Low · 0 → Medium · 16

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Reinsurance Group Of America IncRGA

    8-K · Item 2.02 — Results of operations

    RGA reported Q3 2026 net income of $6.92 per diluted share (vs. $3.81 prior year) and adjusted operating income of $8.49 per diluted share (vs. $4.66 prior year). Strong investment performance, favorable claims experience, and robust premium growth across regions drove results.

    Value: Balanced 52 → Balanced 48

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Aspen Aerogels IncASPN

    8-K · Items 2.02, 5.02 — Results of operations

    Q3 2026 revenue of $85.2M (+71% QoQ, above guidance); Adjusted EBITDA $19.8M (above high end); entered data center infrastructure market; secured 2027 project; record EU OEM revenue.

    Gap Low · 0 → Medium · 21

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Halozyme Therapeutics, Inc.HALO

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 39% YoY to $493M; royalty revenue up 44% to $341M. Company raised full-year 2026 guidance across all metrics. Three ENHANZE programs advanced to Phase 1; expanded partnerships with argenx, Incyte, and J&J. Dutch court granted injunction against Merck's Keytruda Qlex in eight European markets.

    Recognition: Very strong 86 → Very strong 80Value: Watch 38 → Balanced 61Gap Low · 3 → Medium · 10

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Comstock Resources IncCRK

    8-K · Item 2.02 — Results of operations

    Q3 2026 production grew 9% YoY; $1.65B SOCAR divestiture announced to strengthen balance sheet; bank facility extended to 2028/2031; operating cash flow $208M; adjusted EBITDAX $266M.

    Recognition: Watch 27 → Watch 33

    More of the market is starting to notice.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    LifeStance Health Group, Inc.LFST

    8-K · Item 2.02 — Results of operations

    LifeStance reported Q3 2026 revenue of $455.9M (+25% YoY), net income of $22.4M vs. $1.1M prior year, and Adjusted EBITDA of $68.4M (+70% YoY). Company raised full-year 2026 guidance across all metrics: revenue to $1.741–$1.761B, Center Margin to $599–$613M, and Adjusted EBITDA to $242–$250M.

    Gap Low · 6 → Medium · 12

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    First Advantage CorpFA

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 13.8% YoY to $465.8M with 29.3% Adjusted EBITDA margin. Net income surged to $20.5M (vs. $2.6M prior year). Company raised full-year 2026 guidance across all metrics and announced Data Diver Technologies acquisition to enhance AI-driven screening capabilities.

    Gap High · 25 → High · 35

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    MidCap Financial Investment CorpMFIC

    8-K · Item 2.02 — Results of operations

    MFIC announced Q3 2026 results showing net investment income decline to $0.34/share (vs. $0.40 prior quarter), NAV per share fell 3.8% to $12.86, and net realized losses of $44M. Company agreed to be acquired by Ares Capital at $10.88/share.

    Gap Medium · 23 → Low · 4

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Graham CorpGHM

    8-K · Item 2.02 — Results of operations

    Graham Corp reported Q2 FY27 results with 6% revenue growth to $69.8M, gross margin expansion of 650bps to 28.2%, and 39% EPS growth to $0.39. Record backlog of $561.3M (7th consecutive quarter) and strong cash generation of $46.7M. Reaffirmed full-year guidance.

    Recognition: Balanced 48 → Balanced 52Value: Weak 18 → Watch 25Gap Very high · 49 → Very high · 54

    More of the market is starting to notice.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Geo Group IncGEO

    8-K · Item 2.02 — Results of operations

    GEO reported Q3 2026 revenues of $761.1M (+12% YoY), adjusted net income of $51.8M (+48% YoY), and adjusted EBITDA of $145.3M (+21% YoY). Full-year guidance raised across all metrics. Major wins include $500M in new/expanded contracts YTD and $950M Adelanto facility sale.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    TripAdvisor, Inc.TRIP

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue declined 11% YoY to $436.4M. GAAP net loss of $316.9M driven by $369.5M goodwill impairment in Hotels segment. Adjusted EBITDA fell 34% to $71.1M. Company initiated restructuring targeting $40M annualized savings.

    Recognition: Watch 44 → Watch 41Value: Strong 73 → Very strong 87

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Wendy's CoWEN

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show significant deterioration: global systemwide sales down 5.9%, U.S. same-restaurant sales down 5.7%, net income down 65.9% YoY, adjusted EBITDA down 17.8%. Company launched Dave's Way strategy and signed LOI to acquire 163 Meritage restaurants, but near-term performance remains weak.

    News flow: Balanced 49 → Watch 44Recognition: Watch 42 → Balanced 46

    The filings read less positively.

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Climb Bio, Inc.CLYM

    8-K · Item 2.02 — Results of operations

    Climb Bio reported Q3 2026 results with positive clinical data across two lead programs. CLYM116 Phase 1 showed sustained >90% APRIL suppression supporting Q12W dosing; NAVIGATE-2 Phase 2 initiated. Budoprutug demonstrated B-cell depletion and immunologic remission in pMN; additional Phase 1b data in SLE and ITP ongoing. Cash position of $227.6M funds operations into H2 2028.

    Gap Very high · 57 → Very high · 62

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Lantheus Holdings, Inc.LNTH

    8-K · Item 2.02 — Results of operations

    Q3 2026: Revenue $389.9M (+1.5% YoY), adjusted EPS $1.68 (+32.3% YoY). FDA approved TAUKLARIFY and BRAVNETSA. Pending $8B Curium merger at $102.50/share plus up to $12/share CVRs.

    Recognition: Balanced 55 → Balanced 50

    Market attention has faded.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Cars.com Inc.CARS

    8-K · Item 2.02 — Results of operations

    Cars.com reported Q3 2026 net income up 113% YoY to $16.3M on flat revenue of $181.9M. Adjusted EBITDA margin of 30.7% exceeded guidance by 120 bps. Marketplace revenue grew 5% YoY; Premium+ adoption reached 12%. Company reaffirmed full-year guidance.

    Recognition: Balanced 55 → Balanced 62Gap Low · 0 → Low · 3

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Disc Medicine, Inc.IRON

    8-K · Item 2.02 — Results of operations

    Disc Medicine's Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in erythropoietic protoporphyria. NDA resubmission planned by end-2026 with FDA decision anticipated mid-2027. Strong cash position of $683M extended to 2030.

    Gap High · 31 → High · 36

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Rigel Pharmaceuticals IncRIGL

    8-K · Item 2.02 — Results of operations

    Q3 2026: $80.9M revenues (+13% YoY), $13.2M net income. VEPPANU launch generated $6.6M in initial sales. Full-year guidance raised to $290–295M. R289 Phase 1b ongoing; Phase 2 dose selection expected by end-2026.

    Recognition: Balanced 60 → Balanced 57Gap High · 27 → High · 38

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Gold.com, Inc.GOLD

    8-K · Item 2.02 — Results of operations

    Gold.com reported Q1 FY2027 earnings with $0.05 diluted EPS (vs. -$0.04 YoY), $1.6M net income, and $17.4M EBITDA. Gross margin expanded to 2.74% despite 11% revenue decline. Company declared $0.20/share dividend and highlighted acquisition synergies.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    PERDOCEO EDUCATION CorpPRDO

    8-K · Item 2.02 — Results of operations

    Q3 2026 earnings per diluted share increased 16.7% YoY to $0.70; adjusted EPS grew 18.5% to $0.77. Revenue up 1.9% to $215.9M; operating income up 8.1%. Full-year 2026 EPS guidance raised to $2.93–$2.97 vs. prior $2.42.

    Recognition: Watch 37 → Watch 33Value: Strong 72 → Strong 76Gap High · 35 → Very high · 48

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Mannkind CorpMNKD

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenues grew 24% YoY to $101.9M, driven by Furoscix ReadyFlow rapid adoption (75% of shipments) and Afrezza pediatric launch success. Commercial product revenue doubled to $45M. Pipeline advanced with positive Phase 1b nintedanib DPI results.

    Gap Very high · 83 → Very high · 86

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Zenas BioPharma, Inc.ZBIO

    8-K · Item 2.02 — Results of operations

    Zenas reported Q3 2026 results with FDA acceptance of obexelimab BLA (PDUFA May 27, 2027), EMA MAA validation for IgG4-RD, positive Phase 3 INDIGO extension data, and $647.1M cash. Phase 2 SunStone SLE and ZB021 Phase 1 data expected Q4 2026.

    Gap Very high · 57 → Very high · 64

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    ICF International, Inc.ICFI

    8-K · Items 2.02, 8.01 — Results of operations

    Recognition: Balanced 46 → Watch 40Gap High · 27 → Very high · 51

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Sarepta Therapeutics, Inc.SRPT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenues of $323.8M in net product sales; non-GAAP operating income of $22.9M; raised full-year revenue guidance by $50M; MAD data expected Q4 2026 for DM1 and FSHD programs; $998.7M cash position supports late-stage development.

    Gap Low · 0 → Low · 8

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    American Healthcare REIT, Inc.AHR

    8-K · Item 2.02 — Results of operations

    AHR reported Q3 2026 results with strong Same-Store NOI growth (13.8% total portfolio, 28.2% SHOP, 15.7% ISHC). Company raised full-year 2026 guidance for NFFO per share ($2.23–$2.26) and Same-Store NOI growth (12.0%–14.0%). Acquired $1.69B in new SHOP assets; improved leverage to 1.9x Net Debt-to-Annualized Adjusted EBITDA.

    Recognition: Strong 77 → Very strong 80Gap Medium · 13 → Medium · 16

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Cogent Biosciences, Inc.COGT

    8-K · Item 2.02 — Results of operations

    Cogent reports Q3 2026 results with three imminent FDA PDUFA action dates for bezuclastinib (GIST Nov 30, NonAdvSM Dec 30, AdvSM Jun 29, 2027). Cash position of $791.1M funds operations into late 2028. Commercial team in place; pipeline expansion ongoing.

    Gap High · 36 → High · 33

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Gyre Therapeutics, Inc.GYRE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue $32.9M (flat YoY); net loss $2.5M vs. prior profit. FY2026 guidance affirmed at $100.5–$111.0M. F351 NDA under NMPA review; multiple pipeline programs advancing toward clinical initiation in 2027.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Lexicon Pharmaceuticals, Inc.LXRX

    8-K · Item 2.02 — Results of operations

    Lexicon completed enrollment in Phase 3 SONATA-HCM trial (542 patients, exceeding target) with top-line data expected Q1 2027. STENO1 safety data supports ZYNQUISTA NDA resubmission planned Q1 2027. LX9851 Phase 1 ongoing; Lexicon earned $75M of $1B potential milestones from Novo collaboration.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Kratos Defense & Security Solutions, Inc.KTOS

    8-K · Item 2.02 — Results of operations

    Kratos reported Q3 2026 revenues of $471.8M (35.7% growth, 23.2% organic), bookings of $1.037B (2.2:1 book-to-bill), record backlog of $2.65B, and Adjusted EBITDA of $50.9M (10.8% margin). Raised FY2026 guidance and provided FY2027 forecast of $2.1–$2.2B revenue and $230–$240M Adjusted EBITDA.

    Value: Watch 36 → Watch 40Gap High · 39 → Very high · 51

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Netscout Systems IncNTCT

    8-K · Item 2.02 — Results of operations

    NetScout reported Q2 FY2027 revenue of $222.2M (+1.4% YoY), with operating margin expansion and reaffirmed full-year guidance of $885–$915M revenue. Service revenue grew 6.4%; product backlog declined. Company repurchased $77M in stock.

    Recognition: Watch 39 → Watch 31Value: Balanced 56 → Balanced 62Gap Low · 5 → Medium · 20

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Starling Oncology, Inc.STLN

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 24.3% YoY to $169.8M; gross profit surged 62.1%. Adjusted EBITDA turned positive at $3.4M (vs. $(3.5)M prior year), exceeding Q3 guidance. Company affirmed full-year 2026 guidance with improved Adjusted EBITDA range ($4–6M vs. $2–7M prior).

    Recognition: Watch 43 → Watch 32

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Akamai Technologies IncAKAM

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue $1.122B (+6% YoY), driven by Cloud Infrastructure Services +34% YoY. Company projects 2027 revenue growth of 17–22% YoY and 2028 revenue exceeding $7.0B, supported by $14B in multi-year CIS commitments signed YTD.

    Value: Balanced 51 → Watch 26Gap Very high · 57 → Very high · 62

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Enovis CORPENOV

    8-K · Item 2.02 — Results of operations

    Q3 2026: 5% organic sales growth, Reconstructive segment +6%, adjusted EBITDA and EPS guidance raised. Board approved $200M share repurchase authorization. Company executing innovation strategy despite market headwinds.

    Recognition: Balanced 61 → Strong 70Gap Low · 0 → Low · 7

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Tejon Ranch CoTRC

    8-K · Item 2.02 — Results of operations

    Q3 2026 net income increased 94% to $3.3M ($0.12/share) vs. $1.7M prior year. Revenues rose 70% to $25.0M. Adjusted EBITDA grew 96% to $10.4M. Corporate expenses fell 39.8%. All segments showed improvement.

    Gap Low · 4 → Medium · 13

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Lsi Industries IncLYTS

    8-K · Item 2.02 — Results of operations

    LSI reported Q1 FY2027 net sales of $225.9M (+44% YoY), adjusted net income of $11.6M (+$0.31 EPS), and free cash flow of $13.8M. Organic sales declined 2% excluding Royston acquisition. Key wins include 2,500-site refueling refresh and 3,000-store QSR renovation program.

    Gap Very high · 77 → Very high · 83

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Pulse Biosciences, Inc.PLSE

    8-K · Item 2.02 — Results of operations

    Pulse Biosciences completed enrollment of NANOPULSE-AF pivotal study three months ahead of schedule with 169 patients. Company raised $95.8M in Q3 via ATM, ending quarter with $189.2M cash. Vybrance revenue grew to $0.4M; PRECISE-BTN study fully enrolled.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Pdf Solutions IncPDFS

    8-K · Item 2.02 — Results of operations

    PDF Solutions reported Q3 2026 record revenues of $68.3M (+20% YoY), with GAAP gross margin of 73% and operating margin of 12%. GAAP diluted EPS of $0.16 vs. $0.03 prior year. Company reaffirmed 20% annual revenue growth target for 2026.

    Recognition: Balanced 54 → Balanced 51Value: Watch 29 → Watch 33

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Tandem Diabetes Care IncTNDM

    8-K · Item 2.02 — Results of operations

    Q3 2026 sales grew 14% YoY to $283.7M; gross margin expanded 270bps to 57%; operating loss improved 830bps to -1% of sales. Adjusted EBITDA reached $18.0M (6% margin) vs. $2.8M prior year. Pharmacy channel now 15% of U.S. sales; international expansion accelerating.

    Gap Low · 5 → Medium · 15

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Appian CorpAPPN

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 25% YoY to $234.6M; cloud subscriptions revenue up 20% to $136.4M. GAAP net income $12.3M vs $7.8M prior year. Full-year 2026 guidance raised with cloud subscriptions expected at $536–$538M (23% growth).

    Gap Low · 3 → Medium · 10

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Alarm.com Holdings, Inc.ALRM

    8-K · Item 2.02 — Results of operations

    Q3 2026 SaaS revenue grew 9.0% to $191.2M; GAAP net income $34.3M; non-GAAP adjusted EBITDA $66.2M (+19.2% YoY). Company raised full-year 2026 SaaS guidance by $12.2M midpoint and increased adjusted EBITDA outlook. CellGate acquisition and new AI video features announced.

    Value: Watch 38 → Watch 42Gap Low · 4 → Medium · 15

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    HA Sustainable Infrastructure Capital, Inc.HASI

    8-K · Item 2.02 — Results of operations

    HASI reported Q3 2026 Adjusted EPS of $0.82 vs. $0.80 YoY, with YTD Adjusted EPS growth of 15%. Adjusted Recurring Net Investment Income grew 15% YoY to $121M. Managed Assets reached $19.0B (+27% YoY). New investment yields exceed 11%. Reaffirmed 2028 guidance.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    SiriusPoint LtdSPNT

    8-K · Items 2.02, 8.01 — Results of operations

    Q3 2026 net income of $87M ($0.74 EPS) with 19% operating EPS growth. Core combined ratio 90.1%, ROE 15.4%. Loss portfolio transfer with RiverStone expected to unlock $200M+ capital from run-off reserves.

    Recognition: Balanced 61 → Balanced 64Gap Low · 0 → Medium · 16

    More of the market is starting to notice.

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Paylocity Holding CorpPCTY

    8-K · Item 2.02 — Results of operations

    Q1 FY2027 recurring revenue grew 12.0% YoY to $424.5M; total revenue up 10.7% to $451.7M. Net income $57.6M ($1.07/share) vs. $48.0M ($0.86/share) prior year. Company raised full-year FY2027 guidance. Aidora acquisition completed; $152.5M share repurchase executed.

    Gap Low · 4 → Medium · 13

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Dorian LPG Ltd.LPG

    8-K · Item 2.02 — Results of operations

    Dorian LPG reported Q2 FY2027 net income of $213.9M ($4.98 EPS), up 286% YoY, driven by elevated TCE rates ($96,990/day, +80.5% YoY), vessel sales gains ($63.6M), and strong revenues ($221.3M, +78.4% YoY). Declared $1.25/share dividend.

    Recognition: Strong 67 → Balanced 64

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Advanced Drainage Systems, Inc.WMS

    8-K · Items 2.02, 8.01 — Results of operations

    Q2 FY2027: Net sales +4.6% to $889.4M; Adjusted EBITDA $286.8M (32.2% margin). YTD organic sales +2.3%, Adjusted EBITDA +14.0%. Announced StormTrap acquisition. Dividend increased to $0.20/share. Guidance updated; demand softer than expected.

    Gap Very high · 58 → Very high · 71

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Nerdwallet, Inc.NRDS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 11% YoY to $239.6M, but operating income fell 44% YoY to $19.4M and net income declined 43% YoY to $14.9M. Non-GAAP operating income and adjusted EBITDA also declined significantly YoY.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Ducommun Inc /De/DCO

    8-K · Item 2.02 — Results of operations

    Ducommun reported Q3 2026 record revenue of $227.0M (+6% YoY) and record gross margin of 28.9% (+140 bps). Net income $13.9M vs. prior-year loss of $60.8M. RPO at all-time high of $1.3B; defense book-to-bill 2.2x.

    Recognition: Watch 34 → Watch 28

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Ingredion IncINGR

    8-K · Item 2.02 — Results of operations

    Value: Strong 79 → Very strong 82

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Americold Realty TrustCOLD

    8-K · Item 2.02 — Results of operations

    Americold reported Q3 2026 results with 4.2% YoY revenue growth, 6.0% same-store NOI growth, and maintained Adjusted FFO of $0.35/share. Company raised full-year AFFO guidance to $1.31–$1.33/share and reduced debt by $1.15B via EQT joint venture closing, improving net leverage by one turn.

    Gap High · 44 → Very high · 47

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Vontier CorpVNT

    8-K · Item 2.02 — Results of operations

    Q3 2026 results exceeded guidance with adjusted EPS of $0.92 and 12.1% adjusted operating profit growth. Company raised full-year adjusted EPS guidance to $3.60–$3.64. Core sales grew 5.7% despite 2.1% reported sales decline due to divestiture.

    Recognition: Balanced 60 → Strong 71Gap Low · 3 → Low · 9

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Papa Johns International IncPZZA

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show significant declines: global system-wide sales down 5.6%, North America comparable sales down 8.3%, net income down 27%, adjusted EBITDA down 20%. Company lowered full-year guidance materially across key metrics.

    Value: Balanced 59 → Watch 44

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Banks

    GPGI, Inc.GPGI

    8-K · Items 2.02, 8.01 — Results of operations

    GPGI lowered FY26 Adjusted EBITDA guidance by ~$45M (~8%) and Adjusted Free Cash Flow by ~$25M (~8%) due to Husky margin headwinds from delayed cost actions, freight costs, and mix, despite maintaining prior sales forecast and declaring quarterly dividend.

    Recognition: Watch 40 → Balanced 51Gap Very high · 86 → Very high · 69

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    BKV CorpBKV

    8-K · Item 2.02 — Results of operations

    Q3 2026: BKV reported net income of $29.4M ($0.27/share), adjusted net income of $39.9M ($0.36/share), and adjusted EBITDAX of $132.7M. Key wins include cost reimbursement agreement expanding Temple modular power from 200MW to 400MW, backstop agreement with investment-grade hyperscaler for 1.2GW CCGT equipment, and Verra carbon credit certification enabling CSG monetization.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Installed Building Products, Inc.IBP

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 3.9% to record $808.4M, but net income fell 20% YoY to $59.4M. Adjusted EBITDA declined 8.3% to $128.3M with margin compression from 18.0% to 15.9%, driven by residential weakness, cost inflation in fuel/aluminum, and unfavorable segment mix.

    Recognition: Watch 31 → Watch 37

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Sabre CorpSABR

    8-K · Item 2.02 — Results of operations

    Sabre reported Q3 2026 revenue of $738M (+3% YoY), exceeded Adjusted EBITDA guidance, achieved fifth consecutive quarter of double-digit Normalized Adjusted EBITDA growth (+13% YoY to $170M), and raised full-year 2026 Pro Forma Adjusted EBITDA and Free Cash Flow guidance for the second consecutive quarter.

    Value: Very strong 83 → Strong 78

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Shattuck Labs, Inc.STTK

    8-K · Item 2.02 — Results of operations

    Shattuck Labs initiated Phase 2b trial (RECEPTIVE-CD1) for SL-325 in Crohn's disease with 12-week data expected H1 2028, announced Phase 2 trial (RECEPTIVE-HS1) in hidradenitis suppurativa starting Q4 2026, and presented preclinical data for SL-846 bispecific candidate showing favorable tolerability and blockade profiles.

    Recognition: Watch 39 → Watch 36Gap Medium · 24 → High · 37

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Construction Partners, Inc.ROAD

    8-K · Item 2.02 — Results of operations

    FY2026 preliminary results show ~30% revenue growth to $3.66–3.68B and ~40% net income growth to $141.5–142.5M. FY2027 outlook guides 15% growth at midpoint. Company completed acquisition of Piedmont Paving in Georgia and three additional acquisitions early in FY2027.

    Recognition: Balanced 53 → Balanced 50

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Omada Health, Inc.OMDA

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $91M (+34% YoY) exceeded expectations; gross margin expanded to 76%; net income $7M vs. loss of $3M prior year. Total members reached 1.1M (+36% YoY). Full-year 2026 guidance raised significantly.

    Recognition: Balanced 58 → Balanced 51Gap Low · 0 → Medium · 12

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Honest Company, Inc.HNST

    8-K · Item 2.02 — Results of operations

    HNST reported Q3 2026 results with 9.2% organic revenue growth, record 48.9% adjusted gross margin (+1,160 bps YoY), and raised FY2026 guidance. Company approved $30M share repurchase and generated $30.5M free cash flow YTD.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Texas Roadhouse, Inc.TXRH

    8-K · Items 2.02, 8.01 — Results of operations

    Q3 2026 revenue grew 9.5% YoY to $1.57B; comparable restaurant sales increased 4.3%; diluted EPS rose 8.6% to $1.36. Board approved $0.75/share quarterly dividend. Management guides positive comp sales for 2027 with 5-6% store growth.

    Value: Balanced 49 → Watch 44Gap Low · 2 → Medium · 12

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Ginkgo Bioworks Holdings, Inc.DNA

    8-K · Item 2.02 — Results of operations

    Ginkgo reported Q3 2026 revenue of $28M (flat YoY), improved net loss to ($41)M from ($73)M YoY, and announced first autonomous lab sale to Novo pharma plus $17.5M ARPA-H subcontract and NSF/X-Labs partnerships.

    Recognition: Balanced 62 → Strong 68

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Century Aluminum CoCENX

    8-K · Item 2.02 — Results of operations

    Century Aluminum reported Q3 2026 net income of $302.6M (+21% QoQ), driven by Line 2 restart at Grundartangi facility reaching near-full production and favorable metal prices. Adjusted EBITDA $331.6M (+1.4% QoQ); Q4 guidance $275–300M.

    Gap Low · 0 → Low · 9

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Palvella Therapeutics, Inc.PVLA

    8-K · Item 2.02 — Results of operations

    FDA accepted NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review; PDUFA target date February 28, 2027. Company advancing commercial launch preparations for H1 2027 if approved. Strong cash position of $236.7M.

    Recognition: Balanced 49 → Balanced 53Gap High · 34 → High · 39

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Castle Biosciences IncCSTL

    8-K · Item 2.02 — Results of operations

    Castle Biosciences reported Q3 2026 revenue of $102.9M (+24% YoY), driven by 47% growth in TissueCypher test volume. Company raised full-year 2026 revenue guidance to $385–395M from $365–375M and maintains positive Adjusted EBITDA expectations.

    Gap Low · 3 → Medium · 11

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Vistance Networks, Inc.VISN

    8-K · Items 2.02, 8.01 — Results of operations

    Q3 2026 revenue declined 5.4% YoY to $319.7M. Despite improved profitability metrics, company revised full-year adjusted EBITDA guidance downward to $180–200M from prior expectations, citing customer demand pushed into 2027 and memory chip pressures.

    Recognition: Balanced 55 → Balanced 51Value: Very strong 88 → Very strong 98Gap Very high · 65 → Very high · 55

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Teradata Corp /De/TDC

    8-K · Item 2.02 — Results of operations

    Teradata reported Q3 2026 results with modest ARR growth (1% YoY, 2% constant currency) and strong public cloud ARR growth (11%), but total revenue declined 4% YoY. Company narrowed full-year revenue guidance to high-end of range and reaffirmed ARR and free cash flow targets. Q4 guidance shows revenue decline.

    Recognition: Strong 65 → Balanced 62

    Market attention has faded.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    CareTrust REIT, Inc.CTRE

    8-K · Item 2.02 — Results of operations

    Q3 2026: Normalized FFO/FAD per share up 20% YoY to $0.54/$0.53. Company raised full-year 2026 guidance (FFO +18.5%, FAD +16.2% vs 2025). Closed $733M of $1.1B LNT UK care homes acquisition; $2.9B invested YTD at 8.1% yield. Leverage 1.4x, well below 4-5x target.

    Gap High · 44 → Very high · 49

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Globus Medical IncGMED

    8-K · Items 2.02, 8.01 — Results of operations

    Q3 2026 revenue of $763.7M declined 0.7% YoY; company lowered full-year 2026 guidance to $3.09B (5.1% growth) from prior range of $3.18–$3.22B. International sales fell 5.7%. Base business grew 3.0%, but overall results missed expectations.

    Recognition: Watch 37 → Watch 40Value: Very strong 85 → Very strong 88Gap Low · 5 → Low · 0

    The shares became cheaper on AIR's value read.

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Green Plains Inc.GPRE

    8-K · Item 2.02 — Results of operations

    Green Plains reported Q3 2026 net income of $85.4M ($1.03 EPS) vs. $11.9M ($0.17 EPS) prior year. Record adjusted EBITDA of $118.0M driven by 45Z tax credits and improved crush margins. Executed $250–325M 45Z monetization agreement.

    Gap High · 29 → High · 39

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    A10 Networks, Inc.ATEN

    8-K · Items 2.02, 8.01 — Results of operations

    A10 Networks reported Q3 2026 revenue of $91.5M (+22.6% YoY), beating prior guidance. Full-year revenue guidance raised to ~16% growth from 12-14%. Non-GAAP EPS guidance increased to $1.08-$1.10 (20-22% growth). Board approved $0.06/share quarterly dividend.

    Value: Weak 18 → Weak 13Gap High · 42 → Very high · 54

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Semiconductors

    Arteris, Inc.AIP

    8-K · Item 2.02 — Results of operations

    Q3 2026: Revenue $25.8M (+48% YoY), ACV+royalties $103.8M (+39% YoY), RPO $135.5M (+29% YoY). Surpassed 1,000 design starts milestone. Major deals with hyperscaler, semiconductor leaders, automotive OEM. FY2026 revenue guidance raised to $98.5–$99.5M.

    Value: Watch 35 → Watch 28Gap Medium · 23 → High · 38

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Power Solutions International, Inc.PSIX

    8-K · Item 2.02 — Results of operations

    Recognition: Watch 28 → Watch 25Value: Watch 43 → Balanced 59

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Abacus Global Management, Inc.ABX

    8-K · Items 2.02, 8.01 — Results of operations

    Abacus reported record Q3 2026 revenue of $76.9M (+22% YoY), adjusted net income of $29.4M exceeding guidance, and raised full-year 2026 adjusted net income guidance to $104.5–$106.5M (up to 24% YoY). Longevity fund inflows surged to $452.4M; completed $400M securitization; declared $0.22 annual dividend.

    Gap Very high · 46 → High · 43

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Camden Property TrustCPT

    8-K · Item 2.02 — Results of operations

    Camden Property Trust reported Q3 2026 results with same-property NOI declining 0.2% YoY and 1.5% sequentially. Core FFO guidance for 2026 held flat, but full-year NOI guidance reduced to -1.5% to -0.5% from prior -0.6%. Effective new lease rates declined 2.0%.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Ecovyst Inc.ECVT

    8-K · Item 2.02 — Results of operations

    Ecovyst reported Q3 2026 results beating guidance with 51% sales growth to $308.6M and Adjusted EBITDA of $61.2M (+6% YoY). Company raised full-year 2026 Adjusted EBITDA guidance to $208–212M from $195–207M, citing strong refining margins, export demand, and successful Calabrian integration.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Core Natural Resources, Inc.CNR

    8-K · Item 2.02 — Results of operations

    CNR reported Q3 2026 net income of $9.0M ($0.18/share) and adjusted EBITDA of $165.2M on $1.1B revenue. Company returned $90M to shareholders, repurchased 930k shares, and secured ~29M tons of future sales commitments at improved prices amid strengthening thermal and metallurgical coal markets.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Northwest Natural Holding CoNWN

    8-K · Item 2.02 — Results of operations

    NW Natural raised 2026 EPS guidance to $3.10–$3.20 from $2.95–$3.15, driven by strong year-to-date performance, constructive regulatory outcomes in Washington and Oregon, and SiEnergy settlement in Texas. Announced 71st consecutive dividend increase, largest since 2012.

    Recognition: Watch 43 → Balanced 46Value: Watch 34 → Watch 30

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Arlo Technologies, Inc.ARLO

    8-K · Item 2.02 — Results of operations

    Arlo reported Q3 2026 results with record subscriptions revenue of $96M (+20% YoY), ARR of $370M (+14% YoY), gross margin expansion of 600bps, adjusted EBITDA up 57.6% YoY, and authorized a new $100M share repurchase program.

    Gap Low · 7 → Medium · 16

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Kontoor Brands, Inc.KTB

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 3% to $685M with adjusted EPS up 40% to $1.50. Full-year adjusted EPS raised to $5.40 (31% growth). Lee divestiture completed for $698M net proceeds; $450M share repurchase planned. 2027 EPS guidance of at least $6.60 (20%+ growth).

    Recognition: Strong 67 → Strong 70Gap Medium · 20 → Medium · 24

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Iovance Biotherapeutics, Inc.IOVA

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue reached record ~$122M (+80% YoY), gross margin improved to ~60%, Amtagvi exceeded 1,000 treated patients. Multiple clinical trials show strong efficacy: 24.6% ORR in mNSCLC, 59.1% in biomarker-selected subset, 55.6% in UPS/DDLPS. Company reaffirms FY2026 guidance of $410–$420M revenue.

    Value: Balanced 61 → Balanced 64Gap Medium · 14 → Medium · 19

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Aclaris Therapeutics, Inc.ACRS

    8-K · Item 2.02 — Results of operations

    Aclaris reported positive Phase 1b results for ATI-052 in atopic dermatitis and asthma, initiated Phase 2b trials for modzatinib in lichen planus, and reaffirmed bosakitug Phase 2 timeline. Cash runway extended to H1 2029 via $50M October offering.

    Gap High · 25 → High · 33

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Cogent Communications Holdings, Inc.CCOI

    8-K · Item 2.02 — Results of operations

    Q3 2026 service revenue declined 1.8% QoQ and 4.4% YoY to $231.2M. Off-net revenue fell 9.3% QoQ. Board suspended dividend program. Partially offset by wavelength revenue growth (+7.8% QoQ, +57% YoY) and adjusted EBITDA margin expansion to 32.0%.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    International Seaways, Inc.INSW

    8-K · Item 2.02 — Results of operations

    Q3 2026 record net income of $344M ($6.90/share), driven by exceptional tanker market conditions and higher spot earnings. Fleet expansion via Bruton acquisition, strong free cash flow of $234M, and record $5.05/share dividend declared.

    News flow: Balanced 55 → Balanced 59Recognition: Strong 72 → Strong 68Gap Very high · 53 → Very high · 82

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Payoneer Global Inc.PAYO

    8-K · Item 2.02 — Results of operations

    Q3 2026: Revenue $276.9M (+2% YoY), volume $25.3B (+13% YoY), B2B volume surged 59% YoY. ARPU grew 18% YoY. Shareholder approved Nuvei merger; targeting mid-2027 close. Obtained payment licenses in Canada and Israel.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Axcelis Technologies IncACLS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $237.8M exceeded expectations with 11.2% YoY growth. Strong bookings reflect broadening recovery across Memory, Power, and General Mature end markets. Record CS&I revenue and healthy cash generation support positive 2027 outlook.

    Gap Low · 3 → Medium · 16

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Innodata IncINOD

    8-K · Item 2.02 — Results of operations

    Recognition: Balanced 45 → Watch 40Gap Very high · 60 → Very high · 71

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Opendoor Technologies Inc.OPEN

    8-K · Item 2.02 — Results of operations

    Opendoor reported Q3 2026 revenue of $1,022M (+12% YoY), homes purchased quadrupled to 4,865 (+316% YoY), market share increased 4.4x to 0.56%, and trailing-twelve-month marketing and operations efficiency improved 57% and 36% respectively.

    Value: Watch 42 → Watch 36Gap Very high · 59 → Very high · 63

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Astrana Health, Inc.ASTH

    8-K · Item 2.02 — Results of operations

    Astrana Health reported Q3 2026 record revenue of $1,023.6M (+7% YoY), record adjusted EBITDA of $77.2M (+13% YoY), and net income of $20.3M (+1,782% YoY). Nine-month results show 33% revenue growth and 39% adjusted EBITDA growth with $105.4M free cash flow.

    Recognition: Watch 38 → Watch 35Value: Balanced 60 → Strong 67

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Rezolute, Inc.RZLT

    8-K · Item 2.02 — Results of operations

    Rezolute reported Q1 FY2027 results with enrollment completion in Phase 3 upLIFT tumor HI study (topline mid-December 2026), 7 of 8 early participants met primary endpoint, and FDA recommended BLA filing for congenital HI despite prior primary endpoint miss.

    Gap Low · 6 → Medium · 20

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Clean Energy Fuels Corp.CLNE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $112.2M (+5.7% YoY) with net loss of $5.7M vs. $23.8M loss prior year. Adjusted EBITDA $27.2M (+57% YoY). Raised full-year EBITDA guidance to $75–80M. RNG volumes +9%, new hydrogen contract, tax credit monetization.

    Recognition: Watch 38 → Watch 43Gap Low · 0 → Medium · 13

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Unity Software Inc.U

    8-K · Item 2.02 — Results of operations

    Unity achieved Q3 2026 record revenue of $622M (+32% YoY), first GAAP profitable quarter since IPO with $122M net income, and Vector grew 126% YoY. Strategic revenue up 59% YoY; Adjusted EBITDA $257M (+136% YoY). Q4 guidance projects 65-67% Strategic revenue growth.

    Recognition: Very strong 86 → Very strong 92Value: Watch 36 → Weak 24

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Krispy Kreme, Inc.DNUT

    8-K · Item 2.02 — Results of operations

    Krispy Kreme reported Q3 2026 results showing improved profitability metrics, increased revenue guidance, reduced leverage, and strong free cash flow improvement. Systemwide sales grew 1.0% in constant currency despite 12.4% net revenue decline from refranchising.

    Recognition: Balanced 46 → Balanced 57

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Savers Value Village, Inc.SVV

    8-K · Item 2.02 — Results of operations

    Q3 2026 net sales grew 8.5% to $463.1M with comp-store sales up 4.2%. Net income $23.4M ($0.15/share); Adjusted EBITDA $75.9M (16.4% margin), marking fourth consecutive quarter of YoY growth. Company raised FY2026 comparable store sales and Adjusted EBITDA guidance.

    Recognition: Watch 43 → Balanced 48Gap High · 35 → High · 42

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Amphastar Pharmaceuticals, Inc.AMPH

    8-K · Item 2.02 — Results of operations

    Amphastar reported Q3 2026 net revenues of $207.6M (+8% YoY), GAAP net income of $37.8M (+118% YoY), and adjusted non-GAAP EPS of $1.14 (+22% YoY). Record BAQSIMI and Primatene MIST sales offset declines in epinephrine and glucagon. Gross margin compressed to 48% from 51.4% due to pricing pressure and manufacturing remediation costs.

    Recognition: Balanced 46 → Balanced 51

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Open Text CorpOTEX

    8-K · Items 2.02, 8.01 — Results of operations

    OpenText reported Q1 FY2027 results with core revenue growth of 2.4% YoY and core cloud revenue growth of 11.2% YoY. Company completed $1.0B debt refinancing, paid down $300M debt, and declared $0.28/share dividend. Net income margin 12.6%, Adjusted EBITDA margin 35.8%.

    Value: Strong 79 → Very strong 83Gap Low · 7 → High · 30

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Tronox Holdings plcTROX

    8-K · Item 2.02 — Results of operations

    Q3 2026 results in-line with guidance but full-year outlook worsened. Middle East conflict caused supply chain disruptions, raw material cost headwinds ($15-20M), and weaker demand. Full-year free cash flow revised to use $25-50M vs. prior expectations.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Semiconductors

    Nlight, Inc.LASR

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $73.8M exceeded guidance high-end (+10.5% YoY). Gross margin expanded to 33.1% (vs. 31.1% prior year). Adjusted EBITDA surged 55.4% to $11.1M. Defense demand remains strong; Q4 guidance $84–90M despite $15M supply-chain delay to H1 2027.

    Recognition: Balanced 48 → Balanced 51Value: Watch 42 → Watch 33

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Centuri Holdings, Inc.CTRI

    8-K · Item 2.02 — Results of operations

    Centuri reported Q3 2026 record revenue of $1.2B (+40% YoY) and gross profit of $113.4M (+45% YoY) with margin expansion to 9.5%. Net income surged 1,174% to $26.9M. Company raised 2026 guidance and provided 2027 targets of mid-teens revenue growth and 8.5–9% gross margin.

    Gap High · 40 → Very high · 50

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.